{
  "id": "61f6048e882a024a10000020",
  "type": "summary",
  "question": "What is the mechanism of action of donanemab?",
  "ideal_answer": "Donanemab is a new monoclonal antibody that uniquely targets A\u03b2(p3-42), a pyroglutamate form of Amyloid-\u03b2 (A\u03b2) exclusively found in plaques.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34585215",
    "http://www.ncbi.nlm.nih.gov/pubmed/34489680",
    "http://www.ncbi.nlm.nih.gov/pubmed/34162295",
    "http://www.ncbi.nlm.nih.gov/pubmed/34769222",
    "http://www.ncbi.nlm.nih.gov/pubmed/33720637",
    "http://www.ncbi.nlm.nih.gov/pubmed/34880449",
    "http://www.ncbi.nlm.nih.gov/pubmed/34536669",
    "http://www.ncbi.nlm.nih.gov/pubmed/34198582"
  ],
  "snippets": [
    {
      "text": "Considering the recent clinical success of donanemab, which targets A\u03b2\u039d3pE, small molecule-based QC inhibitors may also provide potential therapeutic options for early-stage AD treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34536669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, passive immunization of AD patients with Donanemab, an antibody directed against the N-terminus of pyroglutamate A\u03b2, showed beneficial effects in a phase II trial, supporting the concept that N-truncated A\u03b2 is a relevant target for AD therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34489680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The late-stage agents with positive clinical or biomarker data include four antibodies that engage A\u03b2 oligomers (aducanumab, lecanemab, gantenerumab, and donanemab) and ALZ-801, an oral agent that fully blocks the formation of A\u03b2 oligomers at the clinical dose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34198582",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Donanemab (LY3002813) is a new monoclonal antibody that uniquely targets A\u03b2(p3-42), a pyroglutamate form of Amyloid-\u03b2 (A\u03b2) exclusively found in plaques.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34162295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matically changed with the report that passive immunization with donanemab, an A\u03b2pE3-specific antibody, cleared aymloid plaques and stabilized cognitive deficits in a group of patients with mild AD in a phase II trial. This review summarizes the current knowledg",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34880449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tion has dramatically changed with the report that passive immunization with donanemab, an A\u03b2pE3-specific antibody, cleared aymloid plaques and stabilized cognitive deficits in a group of patients with mild AD in a phase II trial. This re",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34880449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "aches targeting pGlu3-A\u03b2 by glutaminyl cyclase (QC) inhibition (Varoglutamstat) or monoclonal antibodies (Donanemab) are currently in clinical development. Here, we ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34769222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "peptide. Donanemab, an antibody that targets a modified form of deposited A\u03b2, is being investigated for the treatment of early Alzheimer's d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33720637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "y, passive immunization of AD patients with Donanemab, an antibody directed against the N-terminus of pyroglutamate A\u03b2, showed beneficial effects in a phase II trial, supporting the concept that N-truncated A\u03b2 is a relevant target for AD therapy. There is ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34489680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s costly. Donanemab (LY3002813) is a new monoclonal antibody that uniquely targets A\u03b2(p3-42), a pyroglutamate form of Amyloid-\u03b2 (A\u03b2) exclusively found in pl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34162295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Donanemab (LY3002813) is an IgG1 antibody directed at an N\u2011terminal pyroglutamate of amyloid beta epitope that is present only in brain amylo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Donanemab (LY3002813) is an IgG1 antibody directed at an N\u2011terminal pyroglutamate of amyloid beta epitope that is present only in brain amyl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u03b2) peptide. Donanemab, an antibody that targets a modified form of deposited A\u03b2, is being investigated for the treatment of early Alzheime",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33720637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nd is costly. Donanemab (LY3002813) is a new monoclonal antibody that uniquely targets A\u03b2(p3-42), a pyroglutamate form of Amyloid-\u03b2 (A\u03b2) exclusively found in plaques.AREAS COVERED: The phase 2 trial of donanemab in participants with early symptomatic Alzheime",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34162295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u03b2) peptide. Donanemab, an antibody that targets a modified form of deposited A\u03b2, is being investigated for the treatment of early Alzheimer's disease.METHODS: We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on positron-emiss",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33720637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Donanemab (LY3002813) is an IgG1 antibody directed at an N\u2011terminal pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques.OBJECTIVES: To assess effects of donanemab on brain amyloid plaque load after single and multiple intravenous doses, as well as pharmacokinetics, safety/tolerability, and immunogenicity.DESIGN: Phase 1b, investigator- and patient-blind, randomized, placebo-controlled study.SETTING: Patients recruited at clinical research sites in the United States and Japan.PARTICIPANTS: 61 amyloid plaque-positive patients with mild cognitive impairment due to Alzheimer's disease and mild-to-moderate Alzheimer's disease dementia.INTERVENTION: Six cohorts were dosed with donanemab: single dose 10-, 20- or 40- mg/kg (N = 18), multiple doses of 10-mg/kg every 2 weeks for 24 weeks (N = 10), and 10- or 20-mg/kg every 4 weeks for 72 weeks (N=18) or placebo (N = 15).MEASUREMENTS: Brain amyloid plaque",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, passive immunization of AD patients with Donanemab, an antibody directed against the N-terminus of pyroglutamate A\u03b2, showed beneficial effects in a phase II trial, supporting the concept that N-truncated A\u03b2 is a relevant target for AD therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34489680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This situation has dramatically changed with the report that passive immunization with donanemab, an A\u03b2pE3-specific antibody, cleared aymloid plaques and stabilized cognitive deficits in a group of patients with mild AD in a phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34880449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Approaches targeting pGlu3-A\u03b2 by glutaminyl cyclase (QC) inhibition (Varoglutamstat) or monoclonal antibodies (Donanemab) are currently in clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34769222",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}